Vaxcyte
Casey Massena is a Senior Scientist specializing in conjugation development at Vaxcyte since April 2024, following a tenure as a Senior Scientist in bioconjugation development at Abzena from August 2022 to April 2024, where leadership in Phase 1 glycoconjugate vaccine and antibody-drug conjugate programs was demonstrated. Prior experience includes a role as a Research Scientist at Code Biotherapeutics, where bioconjugate chemistry and molecular biology techniques were applied to develop non-viral gene therapies, and as a Postdoctoral Scientist at Inimmune, contributing to multiple Phase 1 clinical trials through bioconjugation and characterization efforts. Academic credentials include a PhD in Supramolecular and Organic Chemistry from the University of Montana, complemented by a BA in Religious Studies from Westmont College.
Vaxcyte
2 followers
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.